{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Iyer AS"],"funding":["Centers for Disease Control and Prevention","National Institutes of Health","MassCPR"],"pagination":["eabe0367"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7857394"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(52)"],"pubmed_abstract":["We measured plasma and/or serum antibody responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with SARS-CoV-2 (of which 93% required hospitalization) up to 122 days after symptom onset and compared them to responses in 1548 individuals whose blood samples were obtained prior to the pandemic. After setting seropositivity thresholds for perfect specificity (100%), we estimated sensitivities of 95% for IgG, 90% for IgA, and 81% for IgM for detecting infected individuals between 15 and 28 days after symptom onset. While the median time to seroconversion was nearly 12 days across all three isotypes tested, IgA and IgM antibodies against RBD were short-lived with median times to seroreversion of 71 and 49 days after symptom"],"journal":["Science immunology"],"pubmed_title":["Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients."],"pmcid":["PMC7857394"],"funding_grant_id":["R01 AI146779","T32 GM007753","T32 AI007245","U01CK000490"],"pubmed_authors":["Fischinger S","Charles RC","Becker M","Oliver E","Slater D","Turbett SE","Kamruzzaman M","Schmidt AG","Garcia-Beltran WF","Yu J","Hauser BM","Jones FK","Feldman J","Iafrate AJ","Alter G","Iyer AS","Caradonna TM","Calderwood SB","Kelly M","Nodoushani A","Lauer SA","LaRocque RC","Barouch DH","Miller TE","Harris JB","Yang D","Atyeo C","Li Z","Branda JA","Teng E","Mills R","Ryan ET","Astudillo M","Mellon G","Azman AS"],"additional_accession":[]},"is_claimable":false,"name":"Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.","description":"We measured plasma and/or serum antibody responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with SARS-CoV-2 (of which 93% required hospitalization) up to 122 days after symptom onset and compared them to responses in 1548 individuals whose blood samples were obtained prior to the pandemic. After setting seropositivity thresholds for perfect specificity (100%), we estimated sensitivities of 95% for IgG, 90% for IgA, and 81% for IgM for detecting infected individuals between 15 and 28 days after symptom onset. While the median time to seroconversion was nearly 12 days across all three isotypes tested, IgA and IgM antibodies against RBD were short-lived with median times to seroreversion of 71 and 49 days after symptom","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2025-04-05T12:02:29.849Z","creation":"2021-02-21T06:49:43Z"},"accession":"S-EPMC7857394","cross_references":{"pubmed":["33033172"],"doi":["10.1126/sciimmunol.abe0367"]}}